← ANALYST RATINGS · TIPRANKS
Hims & Hers Health (HIMS): analyst forecast and price target
Analyst consensus
Hold3 Buy11 Hold0 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $32.82, the highest $42.00, the lowest $26.00. The average is +16.9% from the last price of $28.07.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Allen Lutz★★★★★★★★★★#598 · hits 67% · avg +12.3% | Bank of America Securities | $32.00 | Hold | +14.0% | Reiterated | 15.10.26on TipRanks Oct 16 04:55 | +5.7%next day −3.4% | ↗ |
| AI xAi Medical - Care FacilitiesxAI Grok-4 | TipRanks - xAI | $30.00 → $32.00+6.7% | Hold | +14.0% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI DeepSeek Medical - Care FacilitiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $30.00+3.4% | Hold | +6.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI OpenAI Medical - Care FacilitiesOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $31.00+3.3% | Hold | +10.4% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Anthropic Medical - Care FacilitiesAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $32.00+6.7% | Hold | +14.0% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Google Medical - Care FacilitiesGemini 3.1Pro | TipRanks - Google | $31.00 → $33.00+6.5% | Hold | +17.6% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI PerPlexity Medical - Care FacilitiesPerPlexity SonarPro | TipRanks - PerPlexity | $31.00 → $32.00+3.2% | Hold | +14.0% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| Jailendra Singh★★★★★★★★★★#12131 · hits 43% · avg −6.4% | Truist Financial | $32.00 | Hold | +14.0% | Reiterated | 11.09.26on TipRanks 07:50 | −0.6%next day +5.2% · 5 days +1.8% | ↗ |
| Bryan Smilek★★★★★★★★★★#11852 · hits 39% · avg −12.4% | J.P. Morgan | $32.00 | Hold | +14.0% | Initiated | 11.09.26on TipRanks 06:15 | −0.6%next day +5.2% · 5 days +1.8% | ↗ |
| Brian Tanquilut★★★★★★★★★★#1681 · hits 52% · avg +6.6% | Jefferies | $31.00 | Hold | +10.4% | Reiterated | 03.09.26on TipRanks 09:10 | −4.0%next day 0.0% · 5 days 0.0% | ↗ |
| Justin Patterson★★★★★★★★★★#1977 · hits 46% · avg +6.3% | KeyBanc | — | Hold | — | Reiterated | 02.09.26on TipRanks 05:05 | +0.4%next day −4.0% · 5 days −3.4% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $39.00 → $35.00−10.3% | Buy | +24.7% | Reiterated | 20.08.26on TipRanks Aug 21 04:26 | +3.3%next day +5.6% · 5 days −1.7% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $35.00 → $33.00−5.7% | Hold | +17.6% | Reiterated | 12.08.26on TipRanks Aug 11 06:35 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| George Hill★★★★★★★★★★#1126 · hits 54% · avg +9.0% | Deutsche Bank | $25.00 → $26.00+4.0% | Hold | −7.4% | Assigned | 11.08.26on TipRanks 08:50 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Jonna Kim★★★★★★★★★★#3164 · hits 49% · avg +10.0% | TD Cowen | $25.00 → $30.00+20.0% | Hold | +6.9% | Assigned | 11.08.26on TipRanks 07:50 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Craig Hettenbach★★★★★★★★★★#1537 · hits 59% · avg +7.6% | Morgan Stanley | $21.00 → $28.00+33.3% | Hold | −0.2% | Assigned | 11.08.26on TipRanks 07:15 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Maria Ripps★★★★★★★★★★#497 · hits 48% · avg +18.0% | Canaccord Genuity | $40.00 | Buy | +42.5% | Reiterated | 11.08.26on TipRanks 07:05 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Ryan MacDonald★★★★★★★★★★#12366 · hits 37% · avg −11.1% | Needham | $35.00 → $42.00+20.0% | Buy | +49.6% | Reiterated | 11.08.26on TipRanks 07:01 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| David Larsen★★★★★★★★★★#12072 · hits 35% · avg −4.7% | BTIG | — | Hold | — | Assigned | 11.08.26on TipRanks 06:55 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Mark Mahaney★★★★★★★★★★#639 · hits 55% · avg +12.1% | Evercore ISI | — | Hold | — | Reiterated | 11.08.26on TipRanks Aug 10 22:05 | −3.6%next day −2.0% · 5 days −9.8% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | — | Hold | — | Reiterated | 16.04.26on TipRanks 09:55 | +10.9%next day +5.6% · 5 days +3.3% | ↗ |
| Unknown Analyst | Nephron | $35.00 | Buy | +24.7% | Upgrade | 09.03.26on TipRanks 11:35 | +39.9%next day +6.1% · 5 days +13.6% | ↗ |
| Unknown Analyst | Mizuho Securities | $30.00 | Sell | +6.9% | Reiterated | 18.11.25on TipRanks 10:00 | +2.8%next day −1.6% · 5 days 0.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Hims & Hers Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $32.82 at a price of $29.79 (+10.2%); now: $32.82 at $28.07 (+16.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 10 | 8 | 10 | 9 | 7 | 4 |
| Hold | 32 | 21 | 25 | 22 | 27 | 17 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.06 (from $-0.05 to $0.20). Last quarter: $-0.37.
Sales
Next quarter’s sales estimate — $893M (from $884M to $902M). Last quarter: $753M.
Best top-analyst consensus in the sector · Healthcare
About Hims & Hers Health
- CEO: Andrew Dudum
- Employees: 2,442
- 2269 Chestnut Street, San Francisco, CA, 94123, US
- www.hims.com
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
Data from the stock’s TipRanks forecast page, read 48 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗